Why the study?
Do endothelin receptor antagonists ameliorate the course of acute and chronic renal failure?
Do endothelin receptor antagonists ameliorate the course of acute and chronic renal failure?
Endothelin receptor antagonists show potential as a therapeutic strategy for acute and chronic renal failure based on animal models.
Hypothesis-generating for endothelin antagonists in renal failure; human trials required before clinical consideration.
The endothelin system has been identified as having a substantial role in renal failure, both acute and chronic. Beside its well characterised haemodynamic effects, its mitogenic and pro-fibrotic properties have gained increased interest in the pathophysiology of chronic renal failure. This review outlines the role of endothelin in the pathogenesis of various renal diseases with a special focus on the potential of blocking this system with endothelin receptor antagonists. So far, most data were derived from animal models, but they provide strong evidence that endothelin receptor antagonists may represent a powerful therapeutic strategy in ameliorating the course of acute and chronic renal failure.
No takes yet. Share an insight, caveat, or question.
Knoll et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: